Home > Healthcare > Pharmaceuticals > Finished Drug Form > us heparin market
Get a free sample of U.S. Heparin Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of U.S. Heparin Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Notable players operating in the U.S. heparin market include:
Product launches & approvals, partnerships and geographical expansions are the most adopted business strategies to sustain market competition.
Driven by a rising patient pool suffering from chronic illness coupled with increasing demand for anticoagulant products, the U.S. industry size of heparin surpassed USD 623 million in 2019 and is set to expand at more than 7.2% CAGR through 2026.
The venous thromboembolism segment accounted for USD 328 million in 2019 and is likely to grow at a 6.8% rate through 2026 favoured by the rising number of patients requiring heparin for treatment of venous thromboembolism.
The low molecular weight heparin segment revenue in the U.S. was over USD 535.4 million in 2019 and is poised to grow substantially owing to its distinct biochemical and pharmacological properties.
The hospital pharmacy segment held a market share of 54.3% in 2019, and the rising preference of patients towards hospitals due to ease of availability of medicines will boost the market growth.